FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 446 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Coping With Advanced Melanoma and a Second Cancer Diagnosis: A Survivor’s... June 22, 2023 Rationale Explained for Granting EMA Authorisation for Extended Use of Nivolumab... November 18, 2020 How clues from crystals might help us prevent the overtreatment of... June 20, 2023 Many Men with Penile Cancer Do Not Get Recommended Treatments, Study... March 22, 2018 Load more HOT NEWS New Cancer Diagnoses Jump at Age 65, Suggesting People Put Off... EMA Recommends Extension of Therapeutic Indications for Rucaparib Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer Cancer in My Community: Working Toward Early Diagnosis for Children With...
